Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cytomegalovirus (CMV) Infection Clear all
Completed Not applicable Interventional

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

NCT00002257
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

NCT00000143
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir implant and oral ganciclovir, Cidofovir intravenous
Device · Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
13 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
19
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

NCT00000989
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Sargramostim, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

NCT00002135
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 4:08 AM EDT
Not listed Not applicable Interventional

Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR

NCT00004573
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
ganciclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 4:08 AM EDT
Completed No phase listed Observational

Cytomegalovirus (CMV) Infection in Amniotic Fluid

NCT00194142
View directory record Official record
Conditions
Pregnancy Complications, Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 7, 2026, 4:08 AM EDT
Enrolling by invitation Phase 4 Interventional

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

NCT07009548
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infection
Interventions
Cytogam
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Letermovir for CMV Prevention After Lung Transplantation

NCT05041426
View directory record Official record
Conditions
Lung Transplant, CMV
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed No phase listed Observational

Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts

NCT00023036
View directory record Official record
Conditions
Sensorineural Hearing Loss, Cytomegalovirus Infection
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
Up to 99 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

NCT01165580
View directory record Official record
Conditions
Cytomegalovirus Infections, Heart Transplantation
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 124 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

NCT00000698
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

NCT04725877
View directory record Official record
Conditions
HIV I Infection
Interventions
VIR-1111, Placebo
Biological · Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS

NCT00002273
View directory record Official record
Conditions
Colitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Study of Prophylactic Vs Preemptive Valganciclovir

NCT00374686
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

NCT05854381
View directory record Official record
Conditions
HIV I Infection
Interventions
VIR-1388, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Not applicable Interventional

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection

NCT00000995
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Zidovudine, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
3
States / cities
San Diego, California • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 7, 2026, 4:08 AM EDT
Not yet recruiting Phase 4 Interventional

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

NCT07571135
View directory record Official record
Conditions
CMV Infection, CMV, CMV Viremia, CMV Disease
Interventions
Letermovir, Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
Elisabeth Kincaide
Government
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

NCT06118515
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection
Interventions
Letermovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 90 Days
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 7, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

NCT00000836
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Sevirumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 7, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

NCT01941056
View directory record Official record
Conditions
Cytomegalovirus Infection, Healthy, no Evidence of Disease
Interventions
multi-CMV epitope modified vaccinia Ankara vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 7, 2026, 4:08 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

NCT07801456
View directory record Official record
Conditions
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions
VIR-1388, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 4:08 AM EDT